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Background: Pheochromocytomas are rare catecholamine-secreting tumors that arise 
from chromaffin tissue within the adrenal medulla and extra adrenal sites 
(paraganglioma). Due to excess secretion of catecholamines, these tumors often cause 
debilitating symptoms ending to death if actions are not taken. Management requires 
competent physician, surgeons and anesthesiologists. 
The main objective the study focused on pattern of presentation and treatment challenges 
of pheochromocytoma patients over a period of 21 years (1992- 2012) 
Methods:This was a retrospective study on patients underwent adrenelectomy at KCMC 
Urology Institute during the course of 21 years and histologically confirmed cases of 
pheochromocytoma were enrolled. A structured data collection sheet was designed with 
parameters of demographic data, disease presentation, investigations done, tumor  
localization, surgical technique and follow up, in a course of overseeing the challenges in 
each step of management. 
Results: A total of 13 patients were included in this study, median age of participants was 
25 years. M:F 6:7. Majority of patients presented with clinical features related to episodic 
elevation of catecholamines. Localization of the tumor was done with ultrasonography, 
Computer Tomography scan and upon surgical exploration.12 cases were found to have 
right side tumor and 1 case was on the left. All cases were operated using the Chevron 
incision as the main surgical approach.12 patients got symptoms cured at the first 3 month 
visit. One died in the ward. 
Conclusion: Upon a study Pheochromocytoma showed to be a rare condition. Despite the 
challenges occurred in managing all the cases, surgery has cured in 99% of all patients 
operated. Radiological investigation was able to localize the tumor in 100% of the patients. 
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Introduction 
Pheochromocytoma is a rare tumor arising from catecholamine-producing cells in the adrenal 
medulla– an intra-adrenal paraganglioma (PGL), according to the World Health Organization 
(2004) classification, Adrenal and extra-adrenal PGLs produce significant amounts of 
catecholamine and give rise to the well-known clinical picture of pheochromocytoma. The 
parasympathetic paraganglioma (mainly in head and neck) rarely produce significant amounts 
of catecholamine.  It is an important, often clinically occult neoplasm with devastating 
consequences if overlooked.[1]The first clinical description of pheochromocytoma was by F. 
Frankel in 1886 through a young female patient with a history of episodic attacks of headaches, 
palpitations and anxiety, died suddenly and postmortem examination revealed bilateral adrenal 
medulla tumors. In 1912 Pick coined the term pheochromocytoma when he was describing the 
dusky (pheo) color (Chromo) of the cut surface of the tumor when exposed to dichromate. The 
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first surgical excision of the pheochromocytoma was reported in 1927 by Roux who described 
removal of suprarenal tumor in patient with two years of episodic vertigo and nausea.[2] 
 
Prevalence of pheochromocytoma isn’t precisely known and large number of patients with 
PHEOs do not present with classic symptoms suggesting that majority of PHEO are not 
diagnosed during life[3] Several studies have revealed familial predisposition in autosomal 
dominant manner.  In a large series of patients screened biochemically for suspicion of PHEO, 
the incidence has been reported to be as high as 1.9%, occurring equally in men and women[5] 
 
The adrenal medulla and ganglia of the sympathetic nervous system (SNS) are derived from the 
embryonic neural crest. The endocrine cells of this sympathoadrenal system synthesize and 
secrete catecholamines and exhibit a characteristic histochemical (chromaffin) reaction when 
treated with oxidizing agents. During the last few years, a considerable amount of new data, 
concerning the genetics of PHEO/PGL, have accumulated and changed the whole approach to 
such patients. It has been shown that in about 25% of cases, PHEO/PGLs develop secondary to 
germ line mutations in any of five susceptibility genes 2,3. 
 
A classic PHEO, a solitary tumor of the adrenal medulla, reminds us of a ‘tip of an iceberg’ the 
expression suggesting beyond a single tumor there is potentially a broader clinical picture 
awaiting exploration. KCMC being a referral center has been receiving complicated cases 
including those of pheochromocytoma. Pheochromocytoma is a life threatening tumor and if left 
untreated it is fatal and mortality approaches 100% due to hypertension with secondary stroke 
and other multi-organs failure. Since there was no collective documented study at the setting, 
this 21-years retrospective study overviewed the pattern of presentation and experience in 
managing the disease.  
Patients and Methods 
This study was a Descriptive Retrospective hospital based study conducted at KCMC referral 
hospital in institute of urology over the past 21 years. All patients who histological confirmed 
having pheochromocytoma were included. Data collected through registry books and medical 
files (1992-2012) were entered into data collection forms designed based on the specific 
objectives. Ethical clearance was obtained at first place. 
Results 
The study involved 13 patients whowere diagnosed histologically with pheochromocytoma 
after adrenalectomy at KCMC for a period of twenty one years. Of these, 7 were female, and they 
were coming from rural area. The Median age of patients was 25 years. 
Clinical features 
Patients with pheochromocytoma presented with different symptoms (Table 1). Eleven patients 
presented with persistent hypertension, two had paroxysmal hypertension.  
 
Biochemical Evaluation and pharmacological tests 
Neither biochemical tests nor pharmacological tests documented including Urine and plasma 
catecholamine, Vinillymandelic acid (VMA) and clonidine tests.  
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Table 1. Associated Symptoms in Pheochromocytoma Patients 
Symptoms 
Patients presented with  
Number (%) 
 
Postural hypotension   
Yes  2 (15.38%) 
No  11 (84.62%) 
  
Headache   
Yes  12 (92.31%) 
No  1 (7.69%) 
  
Anxiety   
Yes  12 (92.31%) 
No  1 (7.69%) 
  
Weight loss  
Yes  6 (46.15%) 
No  7 (53.85%) 
  
Pallor  
Yes  7 (53.85%) 
No  6 (46.15%) 
  
Flushing  
Yes  7 (53.85%) 
No  6 (46.15%) 
  
Generalized Body Malaise  
Yes  1 (7.70%) 
No  12 (92.30%) 
  
Palpitation 13 (100%) 
  




Localization of the tumor 
Localization of the tumor was done with Ultrasound, computer Tomography scan and during 
exploration. All were found unilateral, predominantly on the right side 11 candidates. 
Preoperative preparation 
All hypertensive patients were preoperatively treated with phenoxybenzamine and propranolol 
to control hypertension. Phenoxybenzamine was prescribed 10mg three times a day for the 
duration of two weeks. Experienced anaestheologist was consulted before starting stabilizing 
patients, during pre-operative and intraoperative care with adequate monitoring equipment.  
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A minimum of two units of blood was prepared pre-operative in each patient. All patients were 
adequately given intravenous fluids, Ringer’s lactate and normal saline for volume expansion. 




All 13 patients underwent open laparotomy, transperitoneal approach by Chevron abdominal 
incision was used in all cases. The Adrenal vein was identified and ligated first as shown in 
Figure 1. The tumour was gently handled in all cases. Eleven cases were found with right 
adrenal tumours, while 2 cases were on the left.  Malignancy was reported in one patient. 
Neither tumour dimension nor weight measure were recorded. There were intraoperative 
anaesthetic challenges despite the fact that all the patients records showed stabilized blood 
pressure pre-operative. There were episode of hypertension and hypotension crisis which was 




Patients were closely monitored by checking vitals sign were done in all patients including 
blood pressure and pulse. Twelve (12) out of 13 cases were found to be normotensive in a 
course of three month. Moreover all patients had their blood glucose level checked to detect 
hypoglycemia. One patient who intraoperative was found to have unresectable tumor died one 
week after operation. No patient was followed up by checking level of adrenaline and 










                    
Figure 2. Adrenal vein ligated and resection  
                   continue                        
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This study is similar to previous studies done by Berd[4]showing Pheochromocytoma is a rare 
condition as in 21 years duration only 13 patients were recruited.  Most of the patients in this 
study belonged to younger age group with median age being 25 years. Pheochromocytoma was 
equally found in both males and females in this study similar to other studies done by Young et 
al [6] and a nationwide survey in 2009 by Nurse[7]. All patients were initially diagnosed clinically 
with signs and symptoms of hypertension, headache, palpitation and sweatiness. Data from 
previous studies confirm that pheochromocytoma have to be taken into account in differential 
diagnosis of adrenal incidentilomas and the absence of hypertension doesn’t rule out the 
presence of Pheochromocytoma 30. 
 
The time interval from initial clinical diagnosis to operation time was averaged to 246 days. The 
current study showed all patients manifested with hypertension, palpitation and sweating with 
other clinical features which correlate with other previous studies showing diverse 
manifestation reflecting the variations of hormone secretion, the pattern of release, and the 
individual to individual differences in catecholamine sensitivity.[6,10,17] Tumor localization relied 
on abdominal Ultrasound and CT scan, correlates with other studies which showed 100% 
sensitivity [25] 
There were challenges in obtaining biochemical study in all patients; this can be a reason of 
delay in a diagnosis of the tumor as in similar studies has shown to establish diagnosis in more 
than 95% of cases [19]. There was a significant time lag from diagnosis to the introduction of pre-
operative medications like phenoxybenzmine and phentolamine as per required in our 
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management protocol. These challenges of time lag from diagnosis to operation can be partly 
explained by difficulties in getting the premedication for stabilizing the blood pressure before 
the operation in our local set up. Also diagnosis of the tumor itself needs high clinical suspicious 
index, biochemical evaluation and radiological tumor localization before intervention which 
impose challenge in time lag before resection 
Tumour localization relied on abdominal Ultrasound and CT scan, correlates with other studies 
which showed 100% sensitivity [25].  In this study right adrenal gland was more affected 
compared to the left adrenal gland, in contrast with a study done by Krishnappa et al [12]. which 
showed 5 left adrenal gland out of total 7 cases were affected 
Pre-operatively all cases received phenoxybenzamine in a minimum of four weeks in a dose 
range 20-40mg and propranolol to stabilize hypertension and arrhythmias respectively as in 
previous studies showed. Arterial line placement and preoperative correction of intravascular 
volume was done 17. In our study all patients were evaluated adequately with anaesthesiologist 
and hypertension stabilized with α blocker medications before given β blockers and 
intravenous fluids. 
Intra-operatively anesthesiologists took special consideration to control blood pressure by 
giving phentolamine and propranolol and proper monitoring of all vitals.  
The operative management of patients with pheochromocytoma may be complicated by large 
and potentially lethal swings in blood pressure with high peaks during tumor handling and 
severe hypotension immediately following removal of the tumor [32].  Hypotensive episodes 
occurred intraoperative were managed by volume replacement with crystalloids and blood. 
There was no intra-operative mortality in all patients. 12 patients out of thirteen stabilized 
blood pressure 1 month post-operative during the follow up. This is similar to other literatures 
which concluded that there is little mortality if the patient is prepared well and blood pressure 
stabilized before operation. 
Conclusion 
Pheochromocytoma is a rare condition, challenging in management but surgically cured as 
shown this study. The clinical features of pheochromocytoma vary between hypertension, 
headache and sweating manifest in all cases in current study. Despite the challenges in 
diagnosis, ultrasound and CT scan play a big role in tumor localization. Biochemical studies 
should be initiated in diagnosis of pheochromocytoma which will help to in early diagnosis of a 
condition. 
 
Our patients presented late in our department as they have to pass in different department like 
internal medicine department before they came in urology department which can be one factor 
to explain delay of operation from date of diagnosis. Moreover preoperative medications like 
phenoxybenzamine intraoperative medications e.g. phentolamine had to be purchased by 
patients as they were not locally available and this delayed the operation. 
 
There were challenges in histopathological description of the tumour as in all histology results 
none showed if it is malignant or benign. 
 
Surgery is the main stay of treating pheochromocytoma despite the intraoperative challenges. 
 
Recommendations 
• We need multicenter studies to evaluate magnitude of the problem and long follow up of 
the patients. 
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• Phenoxybenzamine is effective in the preoperative management of Pheochromocytoma. 
Drugs like phenoxybenzamine and phenntolamine should make readily available to 
reduce the duration from diagnosis to operative time. 
• In this study we have seen the importance of CT scan and how have it contributed in 
localization of the tumor. This diagnostic instrument should be available all the time. 
• There is a need to do adrenal autopsy for all the cases that dies with essential 
hypertension and its complications to rule out pheochromocytoma enabling us to have a 
clear picture of disease. 
• There is a need to do a study on follow up of all patients diagnosed with 





To all members of KCMC Urology Institute and pathology department who involved in care of all 
patients who involved in care for those patient enrolled this study. 
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